- BioNotebook: IPOs, pipeline progress amidst bubble talk
- Bimagrumab 3rd Novartis drug to win FDA 'breakthrough' designation
- Won't Elan shareholders nix Theravance deal?
- GSK lays out Japan launch plans
- UCB's Lode Dewulf: 'We can and should talk to patients'
- INTERVIEW: Dr Reddy's CEO on the 'windshield and rear view mirror'